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ABSTRACT
Objectives: The aim of this article is to map the European Organization
for Research and Treatment of Cancer (EORTC) QLQ C-30 onto the
EQ-5D measure to enable the estimation of health state values based on
the EORTC QLQ C-30 data. The EORTC QLQ C-30 is of interest
because it is the most commonly used instrument to measure the quality
of life of cancer patients.
Methods: Regression analysis is used to establish the relationship between
the two instruments. The performance of the model is assessed in terms of
how well the responses to the EORTC QLQ C-30 predict the EQ-5D
responses for a separate data set.
Results: The results showed that the model explaining EQ-5D values
predicted well. All of the actual values were within the 95% conﬁdence
intervals of the predicted values. More importantly, predicted difference in
quality-adjusted life-years (QALYs) between the arms of the trial was
almost identical to the actual difference.
Conclusion: There is potential to estimate EQ-5D values using responses
to the disease-speciﬁc EORTC QLQ C-30 measure of quality of life. Such
potential implies that in studies that do not include disease-speciﬁc mea-
sures, it might still be possible to estimate QALYs.
Keywords: quality adjusted life-years, quality of life, regression modeling,
utility assessment.
Introduction
The most popular form of economic evaluation, and the one
recommended by the National Institute of Health and Clinical
Excellence (NICE), is the cost-utility analysis [1]. In this form of
analysis, the outcomes are measured in terms of quality-adjusted
life-years (QALYs), which combines life-years and quality of life
into one index measure. Quality of life is measured on a scale
ranging from 0 (death) to 1 (full health). Speciﬁc health states are
located on this scale based on individuals’ preferences elicited
using methods such as the visual analog scale (VAS), time trade-
off, and the standard gamble method. The majority view is that
the preferences of the adult population (the taxpayers) are most
appropriate given that they provide the funding for the National
Health Service (NHS) [2]. This means that population values need
to be obtained for all of the relevant health states in the economic
evaluation. Eliciting population’s preferences for every single eco-
nomic evaluation would clearly be prohibitively expensive and
too time consuming. Fortunately, population values are readily
available for several generic quality of life instruments including
the EQ-5D [3] and the SF-6D [4]. To estimate QALYs only the
responses to say the EQ-5D instrument need to be elicited which
can then be transformed into quality of life values by using the
population “tariff.” Because these instruments use broad health
domains, they can be applied to a wide range of conditions.
When the interest is in measuring the quality of life of patients,
disease-speciﬁc instruments are often preferred to generic instru-
ments [5]. Disease-speciﬁc instruments focus on particular health
problems and tend to be more sensitive to clinically impor-
tant differences [5]. Using the generic instruments preferred by
economists, in addition to the disease-speciﬁc instruments, adds to
the burden imposed on patients for completing questionnaires.
Population values, however, are generally not available for disease-
speciﬁc instruments.When using a disease-speciﬁc instrument only,
QALYs can not be estimated and a cost-utility analysis cannot be
performed.
One solution is to “map” disease-speciﬁc measures onto
generic measures. The relationship between the two instruments
can be established using regression analysis on existing data.
Mapping would provide a model that would enable the estimation
of QALYs in trials which did not include any generic instruments.
Mapping between instruments has been attempted by previous
studies with mixed results. Brazier [6] used regression analysis to
attempt to map the disease-speciﬁc instrument, Impact of Weight
on Quality of Life-Lite to the SF-6D. Although the models tended
to perform well in terms of explanatory power, they were weak in
terms of predictive ability. Tsuchiya et al. [7] explored possible
ways of converting disease-speciﬁc measure (Asthma Quality of
Life Questionnaire) to preference-based measure (EQ-5D) using a
range of ordinary least squares (OLS) regression models.
Although fairly stable functional relationships were achieved,
their results showed limited ability to predict accurate EQ-5D
values at an individual level. Brennan and Spencer [8] mapped the
Oral Health Impact Proﬁle onto the EQ-5D. The predicted values
for the hold-out sample were substantially higher than the actual
EQ-5D values.
The aim of this article is to map the European Organization
for Research and Treatment of Cancer (EORTC) QLQ C-30 onto
the EQ-5D measure to enable the estimation of health state values
based on the EORTC QLQ C-30 data. The EORTC QLQ C-30 is
of interest because it is the most commonly used instrument
to measure the quality of life of cancer patients [9]. It has
been translated into more than 65 languages and is used widely
internationally [10]. Given its extensive use, successful mapping
of this measure onto a generic measure could provide a substantial
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beneﬁt. It is also hypothesized that mapping is likely to be more
successful because the instrument includes more general domains
in addition to cancer-speciﬁc symptoms. Some of these more
general domains are similar to the dimensions of the EQ-5D.
Regression analysis is used to establish the relationship between
the two instruments, and the performance of the model is
assessed in terms of how well the responses to the EORTC QLQ
C-30 predict the EQ-5D responses for a separate data set.
Methods
Instruments
The EQ-5D is the generic instrument recommended for use in
economic evaluations by NICE [1]. It classiﬁes patients into one
of 243 health states (ﬁve dimensions, each with three levels) [11].
The ﬁve dimensions are: mobility; self-care; usual activities; pain/
discomfort; and anxiety/depression. The levels of each dimension
are roughly: none, moderate, and severe. The EQ-5D is of dem-
onstrated validity and reliability (for an overview of empirical
evidence, see Brooks [12] and Brazier et al. [13]). Population
values are available for the UK [3], as well as several other
countries.
The EORTC QLQ C-30 is a popular instrument for measur-
ing general cancer quality of life. It covers several health
domains, as well as cancer-speciﬁc symptoms of disease, the side
effects of treatment, psychological distress, physical functioning,
social interaction, global health, and quality of life. Most of the
questions have a hierarchical response (Not at all; A little; Quite
a bit; and Very much), with two questions relying on the use of
a VAS. The raw questionnaire responses are transformed to
produce scores on a set of ﬁve function scales (physical, role,
emotional, cognitive, and social functioning) and nine symptom
scales along with a scale representing global quality of life. The
EORTC QLQ C-30 scale has undergone extensive psychometric
testing based on classical test theory, which has yielded favorable
results [9].
Data
The EORTC QLQ C-30 instrument is mapped onto the EQ-5D
instrument using data from a randomized controlled trial of the
cost-effectiveness of palliative therapies for patients with inoper-
able esophageal cancer [14]. Data are available for 199 patients
(29.8% female, 70.2% male), with an average age of 74.8 years.
Data were collected at a range of between 1- and 3-weekly
intervals from baseline to 90 weeks. The advantage of using this
data set is that there are a sufﬁcient number of patients for each
of the levels of EQ-5D dimensions. The number of individuals
reporting severe problems is often very small, which reduces the
scope for consistent modeling of the data. Table 1 shows the
distributions of the responses to each of the ﬁve EQ-5D dimen-
sions, as well as the mean and range of the EORTC QLQ C-30
scales.
Analysis
Two approaches are taken in terms of modeling the EQ-5D data:
1) the EQ-5D values are modeled as a function of the EORTC
QLQ C-30 data; and 2) the ﬁve EQ-5D dimensions are modeled
as a function of the EORTC QLQ C-30 data. These two
approaches require different regression techniques. The EQ-5D
values are continuous and OLS regression is used. The second
approach models the dimensions of the EQ-5D. The dimensions
in the EQ-5D have three levels. Ordered probit regression is used
to allow for the ordinal nature of the dependent variable.
The EQ-5D values and the EQ-5D dimensions are modeled as
a function of the EORTC QLQ C-30 global health status scale,
the ﬁve function scales, and the nine symptom scales. It is
hypothesized that global health status and the function scales are
highly correlated with the EQ-5D values. The symptoms scales,
with the exception of pain, are less likely to be correlated given
that they are more cancer-speciﬁc. The ﬁve function scales are
estimated assuming equal weighting of the different items which
may not reﬂect patients’ preferences. The analysis is therefore
repeated using the raw responses to each of the EORTC QLQ
C-30 item measures.
For the main analyses, data from all time points are used as
this increases the sample size and therefore the statistical preci-
sion of the estimates. The clustering option is used in STATA
(State Corp, College Station, TX) which allows for the fact that
there are several observations per individual which may not be
independent of each other. It could be hypothesized that the
relationship between the two instruments becomes more robust
over time as individuals become more familiar with the instru-
ments. To explore this hypothesis, the regression models are
reestimated to include interaction terms between the independent
variables and time point at which data are collected.
Performance of the Models
Because the purpose of themodel is to predict EQ-5D values based
on EORTCQLQC-30 data, the predictive ability of the models is
of foremost importance and needs to be tested carefully. Two
approaches are taken: 1) assessing the goodness of ﬁt of the
regression models; and 2) prediction of EQ-5D values for a
separate data set. To assess goodness of ﬁt, the standard measure
of adjusted R2 is used for the OLS regression. A pseudo R2 is
required for the ordered probit regressions. The McKelvey–
Zavoina pseudo R2 is used which is an estimate of the proportion
Table 1 Descriptive statistics
N %
EQ-5D
Mobility
No problems 319 36.4
Moderate problems 507 57.8
Severe problems 51 5.8
Self-care
No problems 622 70.9
Moderate problems 197 22.5
Severe problems 58 6.6
Usual activities
No problems 251 28.6
Moderate problems 386 44.0
Severe problems 240 27.4
Pain
No problems 270 30.8
Moderate problems 543 61.9
Severe problems 64 7.3
Anxiety/depression
No problems 376 42.9
Moderate problems 443 50.5
Severe problems 58 6.6
Mean Range
EQ-5D Value 0.539 -0.594–1.0
EORTC QLQ C-30
Global health status 45.34 0–100
Physical functioning 55.17 0–100
Role functioning 46.50 0–100
Emotional functioning 72.82 0–100
Cognitive functioning 77.08 0–100
Social functioning 59.14 0–100
EORTC, European Organization for Research and Treatment of Cancer.
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of variance explained by the models. This measure most closely
approximates the R2 in OLS regression [15]. It is also informative
to examine the number of correct predictions for each of the
dimensions. TheGoodman andKruskal l is usedwhich represents
the number of correct predictions adjusted for the largest row
marginal.
The second approach involves estimating EQ-5D values for a
separate data set. Data from a trial on radiotherapy after breast
cancer surgery for low-risk elderly women (the Postoperative
Radiotherapy in Minimum Risk Elderly [PRIME] study) were
available for 254 patients with an average age of 72.5 years [16].
Data were collected at four time points; baseline, 3.5 months, 9
months, and 15 months. EQ-5D values are predicted for this data
set using both types of models. When using the ordered probit
models, the predicted EQ-5D dimensions are transformed into
EQ-5D values using the UK population tariff [3]. EQ-5D values
are estimated for the overall sample as well as by time points.
Predictive performance for this data set is assessed in terms of
absolute differences between actual and predicted mean EQ-5D
values, the relative prediction error, and whether actual EQ-5D
values lie within the 95% conﬁdence interval (CI). As well as
statistical signiﬁcance, it is also important to explore whether the
difference in EQ-5D values constitutes a quantitative signiﬁcant
difference. Trivial differences may be statistically signiﬁcant if
sample sizes are relatively large. There are no clear guidelines as to
what constitutes a quantitative signiﬁcant difference and this can
only be determined pragmatically. The “minimal clinically impor-
tant difference” (MCID) for the EQ-5Dhas been suggested as 0.03
because this is the smallest difference in EQ-5D value for moving
from one level to another on any of the ﬁve dimensions [17].
The predicted EQ-5D values are also used to estimate QALYs
and these are compared with the actual QALYs. The interest,
from a trial perspective, is in terms of differences between health
states rather than absolute health state values. When comparing
two alternative interventions, the difference in quality of life
between the two arms is assessed. It is therefore investigated
whether predicted differences in both EQ-5D values and QALYs
between the two arms of the trial are similar to the actual
differences in EQ-5D values and QALYs. Moreover, it is assessed
whether the same conclusion regarding effectiveness would have
been reached using the predicted values rather than the actual
values.
Results
Correlations between the individual responses for each of the ﬁve
EQ-5D questions and for each of the 30 EORTC QLQ C-30
questions were ﬁrst explored. Statistically signiﬁcant correlations
were found between scores for a number of dimensions which
measure similar aspects of quality of life.
Table 2 shows the OLS regression results for the EQ-5D
values. All statistical signiﬁcance levels are at the 95% level. The
coefﬁcient on global health status is positive and statistically
signiﬁcant (P = 0.003). Three of the function scales are statisti-
cally signiﬁcant, namely role functioning (P  0.000), emotional
functioning (P  0.000), and cognitive functioning (P = 0.027).
As hypothesized, pain is a statistically signiﬁcant symptom scale
(P  0.000). Fatigue is also statistically signiﬁcant (P  0.000).
Table 3 shows the ordered probit regression results for each of
the ﬁve EQ-5D dimensions. In the case of mobility, role and
cognitive functioning are statically signiﬁcant (both P  0.000),
as well as fatigue (P = 0.003) and dyspnea (P = 0.004). The same
variables, apart from dyspnea, are statistically signiﬁcant with
respect to self-care [role functioning (P  0.000), cognitive func-
tioning (P = 0.004), fatigue (P = 0.013)] with the addition of
ﬁnancial problems (P = 0.036). In the case of usual activities,
global health status (P  0.000), role functioning (P  0.000),
and fatigue (P = 0.004) are signiﬁcant. In the case of pain, emo-
tional functioning, fatigue, and pain are signiﬁcant [(P = 0.002),
(P = 0.03) and (P  0.000), respectively]. Finally, physical and
emotional functioning are statistically signiﬁcant with respect to
anxiety and depression [(P = 0.006) and (P  0.000), respec-
tively]. Models were also estimated using raw responses to the 31
EORTC QLQ C-30 questions. Similar results were found (full
results can be obtained from the authors). In terms of the inter-
action terms between time and EORTC QLQ C-30 scales, only
the interaction term with pain was statistically signiﬁcant. This
implies that, with the exception of one scale, the relationship
between the scales and the EQ-5D values does not change as
patients become more familiar with the instruments.
Predictive Performance
The goodness of ﬁt statistics for the different regression models
are reported in Tables 2 and 3. The adjusted R2 for the OLS
regression is relatively high, namely 0.611. The McKelvey and
Zavoina’s R2 ranges from 0.370 to 0.668 for the ordered probit
regression. Most models have relatively high R2 indicating that a
relatively large part of the variation is explained by the models.
The models for mobility and self-care seem to perform less well
in terms of goodness of ﬁt. The Goodman and Kruskal l for the
ordered probit regression results, reported in Table 3, show that
the models reduce prediction error by about 35% on average.
The reduction in prediction error is highest for the anxiety and
depression dimension (52.8%) and lowest for the self-care
dimension (9%).
Table 4 shows the predicted EQ-5D values for the PRIME
data set. The EQ-5D values predicted on the basis of the OLS
regression are reported ﬁrst. In terms of the overall sample, the
predicted EQ-5D value is higher than the actual EQ-5D value.
The mean difference is relatively small, namely 0.014. The actual
EQ-5D value of 0.760 is just inside the 95% CI of the predicted
EQ-5D value which ranges from 0.760 to 0.788. The difference
of 0.014 is below an MCID of 0.03. Actual and predicted EQ-5D
values are also reported for each time point. The difference
between actual and predicted values seems to increase over time.
Nevertheless, the actual EQ-5D values are all within the 95% CI
of the predicted EQ-5D values. Moreover, all of the differences
Table 2 Regression results for EQ-5D values
b t-value
Global health status* 0.0016 3.06
Physical functioning 0.0004 1.01
Role functioning* 0.0022 5.26
Emotional functioning* 0.0028 6.16
Cognitive functioning* 0.0009 2.22
Social functioning 0.0002 0.67
Fatigue* -0.0021 -3.76
Nausea/vomiting -0.0005 -1.59
Pain* -0.0024 -6.11
Dyspnea 0.0004 1.46
Insomnia 0.00004 0.14
Appetite loss 0.0003 1.15
Constipation 0.0001 0.64
Diarrhea -0.0003 -0.62
Financial problems -0.0006 -1.41
Constant 0.2376 3.40
Adjusted R2 0.611
N observations 877
*denotes a statistically signiﬁcant attribute.
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are below an MCID of 0.03. The mean QALYs are also reported
in Table 4. Given that the predicted EQ-5D values are lower than
the actual EQ-5D values, it follows that the mean QALYs esti-
mated from predicted EQ-5D values are also higher than the
mean QALYs estimated from actual EQ-5D values. The differ-
ence is equal to 0.018 QALYs. The actual mean QALYs is well
within the 95% CI of the predicted QALYs.
Table 4 also shows the EQ-5D values based on predicted
EQ-5D dimensions from the ordered probit regression results.
The models seem to predict less well as the difference between
predicted and actual EQ-5D values is much larger, namely 0.050.
Moreover, the actual value of 0.760 is outwith the 95% CI of the
predicted EQ-5D value which ranges from 0.797 to 0.822.
The difference of 0.050 is also greater than the MCID of 0.03.
The difference between actual and predicted values again seems
to increase over time. The models also predict less well in terms
of QALYs as the difference between predicted and actual QALYs
is equal to 0.072.
Results by Arm of the Trial
As highlighted before, the real question is whether the differences
in predicted values between the arms of the trial are similar to the
differences in actual values. That is, would the same conclusions
have been reached regarding effectiveness and cost-effectiveness?
In the PRIME study, no statistically signiﬁcant differences
in either the EQ-5D values or QALYs were found between the
two arms of the trial. Table 5 shows the EQ-5D values and
QALYs by arm of the trial based on the predictions from the OLS
regression model. None of the differences in the predicted EQ-5D
values between the two arms of trial are statistically signiﬁcant.
Moreover, the difference in predicted QALYs between the two
arms of the trial is almost identical to the actual difference in
QALYs, namely 0.017 versus 0.019.
Conclusions
The aim of this article was to map the EORTC QLQ C-30 onto
the EQ-5D measure to enable the estimation of health state
values based on the EORTC QLQ C-30 data. Both the EQ-5D
values as well as the EQ-5D dimensions were modeled as a
function of the EORTC QLQ C-30 global health status, func-
tioning, and symptom scales. The predictive ability of the model
was tested on a separate data set. The results showed that the
model explaining EQ-5D values predicted well. All of the actual
Table 3 Regression results for EQ-5D dimensions
Mobility Self-care Usual activities Pain Anxiety/depression
b t-value b t-value b t-value b t-value b t-value
Global health status -0.0048 -1.46 0.0027 0.90 -0.0110 -3.81 -0.0001 -0.04 -0.0009 -0.27
Physical functioning -0.0026 -1.13 -0.0049 -1.97 0.0016 0.74 0.0026 1.11 -0.0063 -2.77
Role functioning -0.0132 -5.20 -0.0133 -5.20 -0.0231 -8.81 0.0040 1.63 0.0019 0.85
Emotional functioning -0.00005 -0.02 -0.0019 -0.67 -0.0040 -1.21 -0.0090 -3.10 -0.0415 -11.35
Cognitive functioning -0.0104 -3.87 -0.0066 -2.85 -0.0019 -0.72 0.0006 0.21 -0.0027 -1.15
Social functioning 0.0014 0.74 -0.0010 -0.49 -0.0022 -1.07 0.0031 1.53 -0.0027 -1.28
Fatigue 0.0112 2.96 0.0078 2.47 0.0085 2.86 0.0073 2.17 0.0051 1.59
Nausea/vomiting 0.0015 0.71 0.0004 0.21 -0.0004 -0.17 0.0035 1.45 0.0010 0.43
Pain -0.0017 -0.72 0.0010 0.41 -0.0012 -0.50 0.0420 12.29 -0.0019 -0.92
Dyspnea 0.0052 2.85 -0.0014 -0.74 -0.0023 -1.40 -0.0020 -1.04 -0.000001 0.01
Insomnia 0.0002 0.12 -0.0007 -0.35 -0.000001 0.01 0.0026 1.50 -0.0024 -1.52
Appetite loss -0.0019 -1.16 -0.0024 -1.26 -0.0001 -0.09 0.0008 0.44 0.0003 0.16
Constipation -0.0017 -1.18 0.0002 0.14 -0.0003 -0.16 0.0019 1.20 0.0005 0.32
Diarrhea 0.0026 0.82 0.0037 1.68 0.0041 1.66 -0.0017 -0.58 -0.0012 -0.37
Financial problems 0.0005 0.22 0.0045 2.09 0.0030 1.30 0.0007 0.30 -0.0010 -0.44
N 877 877 877 877 877
McKelvey and Zavoina’s R2 0.473 0.370 0.621 0.668 0.565
Goodman and Kruskal l 0.289 0.090 0.442 0.425 0.528
Table 4 Predicted versus actual EQ-5D values and quality-adjusted life-years (QALYs)
Actual Predicted (95% CI) Difference Relative prediction error
Predictions based on predicted
values from OLS regression
Mean EQ-5D 0.760 0.774 (0.760–0788) 0.014 1.84%
Mean EQ-5D by time point
Baseline 0.765 0.772 (0.746–0.798) 0.007 0.92%
3.5 months 0.778 0.780 (0.752–0.807) 0.002 0.26%
9 months 0.756 0.780 (0.751–0.808) 0.024 3.17%
15 months 0.741 0.764 (0.735–0.794) 0.023 3.10%
Mean QALYs 0.945 0.963 (0.933–0.9937) 0.018 1.90%
Predictions based on predicted dimensions
from ordered probit regressions
Mean EQ-5D 0.760 0.810 (0.797–0.822) 0.050 6.58%
Mean EQ-5D by time point
Baseline 0.765 0.801 (0.776–0.826) 0.035 4.71%
3.5 months 0.778 0.814 (0.789–0.839) 0.036 4.63%
9 months 0.756 0.824 (0.800–0.848) 0.068 8.99%
15 months 0.741 0.800 (0.773–0.828) 0.059 7.96%
Mean QALYs 0.945 1.017 (0.980–1.054) 0.072 7.62%
CI, conﬁdence interval; OLS, ordinary least squares.
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values were within the 95% CI of the predicted values. More
importantly, the predicted difference in QALYs between the arms
of the trial was almost identical to the actual difference in
QALYs. Using predicted rather than actual values would there-
fore not have changed the conclusions regarding the cost-
effectiveness of the intervention. This indicates that there is
potential to estimate EQ-5D values using responses to the
disease-speciﬁc EORTC QLQ C-30 measure of quality of life.
Such potential implies that in studies that do not include disease-
speciﬁc measures, it might still be possible to estimate QALYs.
The prediction of the EQ-5D values based on predicted levels
for each of the dimensions was less successful. This is most likely
because of the fact that the analysis did not take any correlation
between the dimensions into account because the dimensions
were modeled separately. The use of multivariate analysis might
improve the predictive ability. Unfortunately, multivariate
ordered probit analysis is currently not available within standard
software packages such as STATA and Limdep (Econometric
Software, Plainview, NY).
The mapping was very successful in this study in that the
model predicted the EQ-5D levels and QALYs well for a separate
data set. The question arises whether these results are generaliz-
able. The data used were collected from patients with esophageal
cancer. An advantage of this data set was that there were sufﬁ-
cient numbers of patients in each of the levels of the ﬁve EQ-5D
dimensions. This patient group, however, is unlikely to be repre-
sentative of the “average” cancer patient group. As well as the
type and stage of cancer factors such as age and sex may affect
the predictive performance of the model. Although the results
showed that the model did predict well for a group of patients
with different type of cancer, namely breast cancer, the average
age of the patients was similar in the two data sets. Further
research exploring predictive performance for different patient
groups is clearly required before the application of the model
should become a recommended approach for converting the
EORTC QLQ-C30 data into EQ-5D values.
The data used in this study came from two trials, both funded by the NHS
HTA Programme. The ﬁrst trial is “A pragmatic randomized controlled
trial of the cost-effectiveness of palliative therapies for patients with inop-
erable esophageal cancer”—NHS HTA 96/06/07, and the second trial is
“The PRIME breast cancer trial (postoperative radiotherapy in minimum-
risk elderly)”—NHS HTA 96/03/01. We would like to thank Paul
McNamee for making the ﬁrst set of data available to us. The Chief
Scientist Ofﬁce of the Scottish Executive Health Department (SEHD)
funds HERU. The views expressed in this article are those of the author
only and not those of the funding body.
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Table 5 Actual and predicted EQ-5D values and quality-adjusted life-
years (QALYs) by arm of the trial
Radiotherapy
No
radiotherapy
Difference
between arms t-value
EQ-5D value
Actual 0.765 0.755 -0.010 0.77
Predicted 0.779 0.769 -0.009 0.70
Baseline
Actual 0.764 0.766 0.002 0.07
Predicted 0.770 0.774 0.004 0.15
3.5 months
Actual 0.783 0.773 -0.011 0.47
Predicted 0.784 0.776 -0.008 0.27
9 months
Actual 0.774 0.740 -0.033 1.16
Predicted 0.792 0.768 -0.025 0.85
15 months
Actual 0.743 0.740 -0.003 0.09
Predicted 0.770 0.759 -0.011 0.37
QALYs
Actual 0.954 0.935 -0.019 0.69
Predicted 0.972 0.955 -0.017 0.54
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